Histological analysis performed at the end of the treatment period confirmed that prazosin\treated mice presented smaller tumors than vehicle\treated mice (Fig?2D). receptors. Its off\target activity occurred via a PKC\dependent inhibition of the AKT pathway, which resulted in caspase\3 activation. Blockade of PKC activation prevented all molecular changes observed in prazosin\treated glioblastoma\initiating cells, as well as prazosin\induced apoptosis. Based on these data, we conclude that prazosin, an FDA\approved drug for the control of hypertension, inhibits glioblastoma growth through a PKC\dependent mechanism. These findings open up promising prospects for the use of prazosin as an adjuvant therapy for glioblastoma patients. lacking DNA binding activity (e.g. TG16) (Silvestre prazosin treatment of GBM44\bearing mice. Right panel: quantification of TUNEL\positive glioblastoma cells in vehicle\ versus prazosin\treated mice. Protocol design is schematized in Fig?2A. Mice were sacrificed 48?h after the last prazosin injection. Scale bar:?50?m. Results are presented as mean??SD in biological quadruplicates from three independent experiments. *prazosin treatment does not alter angiogenesis. Representative H&E images of tumors initiated with GBM44 grafting. Mice were treated according to the protocol depicted in Fig?2A and sacrificed 2?days after the last prazosin injection. Arrowheads point to blood vessels. Scale bar:?50?m. Viability analysis of GICs that escaped prazosin treatment. GICs having escaped a first prazosin treatment are responsive to a second prazosin treatment at 30?M. GICs were treated with prazosin for 72?h. The medium was then replaced with fresh medium, and the cells were allowed to recover for 2?weeks prior to be exposed to prazosin for 72?h. Open in a separate window Figure EV2 Extreme limiting dilution assay of GBM44Prazosin inhibits the sphere\forming capability of GICs. Extreme limiting dilution assay. GBM44 cells were seeded in presence of vehicle or 10?M prazosin (PRZ). Sphere formation was scored 21?days post\seeding. Control?=?1/6.32 (lower 15.9, upper 2.72); prazosin 1/248 (lower 85.3, upper 11.4), effect of prazosin on orthotopic glioblastoma xenografts from GICs derived from human glioblastoma samples (GBM5 and GBM44). EGFR+/CD133+ cells, which constitute a population of GICs with a high degree of self\renewal and tumor\initiating ability (Mazzoleni bioluminescent imaging (Fig?2A). Prazosin inhibited glioblastoma growth compared to control in both xenograft models (Fig?2BCD), and KaplanCMeier analysis showed a significant improvement in survival of the groups treated with prazosin as compared to the control groups (Fig?2B and C). Histological analysis performed at the end of the treatment period confirmed that prazosin\treated mice presented smaller tumors than vehicle\treated mice (Fig?2D). Of note, tumors from vehicle\ and prazosin\treated mice presented similar blood vessels density, suggesting that prazosin did not affect angiogenesis (Fig?EV1C). Flow cytometry analysis of GFP\positive tumor cells showed a significant decrease in human CD133\positive cells in prazosin\treated mice, suggesting removal of GICs along with the non\GICs (Fig?2E). To further demonstrate that prazosin affects GICs, we evaluated its effects on a major property of cancer stem cells, tumor initiation. GFP\positive tumor cells from primary tumors were isolated (see Materials and Methods section) and re\injected into new groups of mice (Fig?2F). All mice that were grafted with glioblastoma cells isolated from vehicle\treated mice developed tumors (8/8 cases, Fig?2F). However, only 4/8 mice injected with glioblastoma cells isolated from prazosin\treated mice developed tumors (Fig?2F). Moreover, mice injected with glioblastoma cells isolated from prazosin\treated mice showed a statistically significant survival benefit Efinaconazole ((Fig?3A) and significantly inhibited Efinaconazole tumor growth (Fig?3BCD), an effect associated with a survival benefit (Fig?3C). Finally, using this glioblastoma model coupled with intraperitoneal injections of the green\fluorescent derivative of prazosin, BODIPY FL prazosin, we observed a marked accumulation of prazosin in the tumor within 2?h post\treatment (Fig?3E). Taken altogether, these data show that prazosin inhibits tumor growth initiated by GICs and increases the survival of glioblastoma\bearing mice including at low doses akin to those used in human treatments. Open in a separate window Figure 2 Prazosin inhibits glioblastoma growth effect of prazosin treatment (1.5?mg/kg) on glioblastoma growth. Tumors were initiated with GBM44 GICs (B) or GMB5 GICs (C). Left panels: Bioluminescent images of tumors in Mouse monoclonal to CD8.COV8 reacts with the 32 kDa a chain of CD8. This molecule is expressed on the T suppressor/cytotoxic cell population (which comprises about 1/3 of the peripheral blood T lymphocytes total population) and with most of thymocytes, as well as a subset of NK cells. CD8 expresses as either a heterodimer with the CD8b chain (CD8ab) or as a homodimer (CD8aa or CD8bb). CD8 acts as a co-receptor with MHC Class I restricted TCRs in antigen recognition. CD8 function is important for positive selection of MHC Class I restricted CD8+ T cells during T cell development mice treated with prazosin (PRZ) or vehicle for 45?days. Middle panels: Quantification of the bioluminescent signals. Fold change in total flux represents the ratio: total flux after treatment/total flux before treatment. *images of secondary grafts. Middle panel: Quantification of the bioluminescent Efinaconazole signals. *images of tumors in mice treated with vehicle or prazosin (PRZ) for 45?days. Tumors were initiated with GBM44 GICs (compare with panel B). Middle panel: Quantification of the bioluminescent signals. *of glioblastoma\bearing immunocompetent mice. Prazosin inhibits tumor growth in an immunocompetent model of glioblastoma. Left panel: Bioluminescent images of tumors.